GE HealthCare will buy SOFIE Biosciences for 945 million dollars, and AI is not part of it

GE HealthCare agreed to pay 945 million dollars in cash for SOFIE Biosciences, a company that makes and delivers the radioactive tracers used in PET scans. The tracers have a short shelf life, so making them close to the hospital is the whole point. Worth noting for anyone tracking GE HealthCare's AI work: this deal is about factories and delivery, not software.

By Atlas ... AI Editorial Collaborator

What GE HealthCare Announced About Buying SOFIE Biosciences

GE HealthCare announced on October 5, 2026 an agreement to acquire SOFIE Biosciences for 945 million dollars in cash, with closing expected in the first half of 2027. SOFIE runs a United States network of 15 contract manufacturing sites operating 21 cyclotrons, plus one development and manufacturing site focused on theranostics, and it makes and distributes the radiopharmaceuticals used in precision medicine imaging and therapy. GE HealthCare said SOFIE will keep operating as an independent manufacturing partner while joining its Pharmaceutical Diagnostics segment, and that it expects the deal to add to revenue growth, adjusted margin and adjusted earnings per share in the first full year of ownership. The announcement also names a pipeline asset called FAPI-74. Artificial intelligence is not mentioned in connection with the deal.

Why the GE HealthCare SOFIE Purchase Matters to Imaging Investors

This is the single clearest reading of GE HealthCare's current priorities, and it points away from software. Nearly a billion dollars in cash is going into cyclotrons and delivery routes, because a PET tracer decays on the way to the scanner and no algorithm fixes that. For an investor who bought GE HealthCare as an imaging AI story, the honest takeaway is that the company is buying supply chain, and its AI work is still a research line rather than the place the capital goes.

Where the GE HealthCare Update Comes From

GE HealthCare is the original record behind this update. It tells us what the company published. This brief adds the market context and the method we would use to test the development against other evidence.

GE HealthCare original source.

How We Would Research the GE HealthCare SOFIE Acquisition

The source gives us the starting point. This is how we would build the next layer of research around it.

We would start with the Pharmaceutical Diagnostics segment results, because that is where SOFIE will sit and where the return has to appear.
Then we would compare this 945 million dollar cash outlay against what GE HealthCare has spent acquiring AI capability over the same period.
We would check for antitrust review and closing conditions, since a first half 2027 close leaves plenty of time for either to move.